The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (453 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-04-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 22.8% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cardiacbypassliverundergoingdetermine whether
  Phrases that lowered it: rangetimeshistory ornormalmg
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 29 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Keywords listed: 7 (lowers risk) · Design
• Minimum age: 65 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Preoperative Carbohydrate Load and Intraoperative w3-PUFA in CAGB Surgery NCT03017001 · started 2014 · scored riskier than 6% of active trials completed
• PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients NCT04093219 · started 2020 · scored riskier than 67% of active trials completed
• Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation NCT00970489 · started 2010 · scored riskier than 57% of active trials completed
• A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium NCT00865202 · started 2008 · scored riskier than 27% of active trials completed
• The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial NCT01690988 · started 2014 · scored riskier than 34% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.